NICE put on defensive as ruling on Relenza ends in row over 'leaks'

The National Institute for Clinical Excellence has defended its handling of the fast-track appraisal of Relenza, despite concern about the way news that the anti-flu drug had been turned down for NHS prescription this winter emerged.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here